These findings also give us some hints that the development of CXCL1 and CXCR2 inhibitors based on gut microbiota is expected to alleviate NEC symptoms, and reduce the risk of HIBI complication in infants with NEC, by blocking inflammatory mediators and inhibiting the migration of peripheral neutrophils to the central nervous system, but human-based in vitro and in vivo experiments are still urgently needed. This evidence concerns the gene CXCR2 and necrotizing enterocolitis.